Jun 21 |
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
|
Jun 5 |
Iterum Therapeutics to Present Data at ASM Microbe 2024
|
May 31 |
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
|
May 6 |
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
|
Apr 29 |
Iterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenem
|
Apr 29 |
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
|
Apr 2 |
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript
|
Mar 29 |
Q4 2023 Iterum Therapeutics PLC Earnings Call
|
Mar 28 |
Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript
|
Mar 28 |
Iterum Therapeutics Non-GAAP EPS of -$0.81
|